pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,609 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT834Endpoints640BioPharma Dive243onclive165BioSpace98Fierce Biotech96raps39globenewswire health28fda recalls
therapy area
allOncology5005Rare Disease852Cardiology802Hematology772Immunology736Psychiatry & CNS582Pulmonology
  • Intellia's in vivo CRISPR therapy first to succeed in Phase 3
    An experimental treatment that uses CRISPR to edit genes directly inside the body has just succeeded in a Phase 3 trial — a first for the technology — putting it on track for a potential FDA approv…
    Endpoints · 3mo ago↗ source
  • STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trial
    With good results from Intellia, the CRISPR field faces the question: How attractive will the one-and-done approach be to patients and doctors?
    STAT · 3mo ago↗ source
  • Veradermics wins at growing hair with oral Rogaine in first key test as a public company
    Veradermics has succeeded in its first major test as a newly-minted public company. The biotech's form of oral Rogaine cleared the bar in a Phase 2/3 trial in men with mild-to-moderate pattern hair…
← prev
page 63 of 65
next →
23
fda press21
fda medwatch18
573
Vaccines517
Endocrinology & Metabolism293
Ophthalmology265
Infectious Disease253
Nephrology239
Endpoints · 3mo ago
↗ source
  • AI biotech Fathom raises $47M Series A, renames from Atommap
    In the early 2000s, way before AI became a ubiquitous buzzword in biotech, billionaire scientist David Shaw was building supercomputers to study molecules at his eponymous research company. Huafeng…
    Endpoints · 3mo ago↗ source
  • STAT+: Veradermics’ hair loss drug succeeds in late-stage trial
    The company is one of the most advanced players in the hair loss field, which has seen a surge of investor enthusiasm.
    STAT · 3mo ago↗ source
  • STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage study
    A long-acting injectable treatment for plaque psoriasis helped 63% of patients achieve complete skin clearance in a clinical trial, its maker, Oruka Therapeutics, reported.
    STAT · 3mo ago↗ source
  • STAT+: Zap in a cap: How one neurotech startup is using a hat to treat depression
    FDA approved a request from Motif Neurotech, to start an initial feasibility trial to test a brain implant to treat depression.
    STAT · 3mo ago↗ source
  • NIH-funded research lags in reporting sex differences, new study finds
    Fewer than half of papers published by NIH-funded researchers analyze or report their data by sex, a new study found.
    STAT · 3mo ago↗ source
  • Opinion: I’m a fourth-year med student, but I only learned one historical example of medical racism
    Modern randomized controlled trials often rely on marginalized populations abroad.
    STAT · 3mo ago↗ source
  • Opinion: Patients seeking mental health treatment are not commodities
    Legal agreements that directly shape access to care remain invisible to the very people whose lives they govern.
    STAT · 3mo ago↗ source
  • What happened to Covid?
    The thinking about what risk Covid poses — or doesn't pose — has shifted in recent years. What does it mean for you?
    STAT · 3mo ago↗ source
  • Sun Pharma to buy Organon for $11.75B in major portfolio expansion
    Indian drug giant Sun Pharma has lined up an $11.75 billion acquisition of Organon, a women’s health and biosimilar maker spun out of Merck in 2021. The all-cash deal came in at $14 per share ...
    Endpoints · 3mo ago↗ source
  • Investment in UK biotechs shows early signs of recovery, report says
    After a lull in mid-2025, investment in UK biotechs appears to be picking up, according to data from the UK trade group the BioIndustry Association. In the first quarter of 2026, total equity fundi…
    Endpoints · 3mo ago↗ source
  • STAT+: Doctor, wife of acting U.S. attorney general, appointed to NIH advisory council
    An integrative medicine doctor who is the wife of the acting U.S. attorney general has been named as a member to one of the advisory councils that provides critical funding…
    STAT · 3mo ago↗ source
  • Nancy Cox, a CDC veteran and a stalwart in global flu research, dies at 77
    Nancy Cox, a CDC veteran who for decades was a global leader in influenza research, has died at 77.
    STAT · 3mo ago↗ source
  • Opinion: The podcast telling the stories behind Ambien, Ozempic, EpiPens, and other game-changing drugs
    “We're basically not using our body as directed,” says "Drug Story" host Thomas Goetz.
    STAT · 3mo ago↗ source
  • Sanofi’s immunology reckoning; Lilly acquires in vivo CAR-T biotech; RevMed’s ‘Herceptin moment’; and more
    Welcome back to another edition of Endpoints Weekly! We’re doing a little bit of celebrating here at Endpoints, as we took home three Neal Awards, which recognize excellence in B2B journalism. The ...
    Endpoints · 3mo ago↗ source
  • STAT+: FDA to speed up review of three psychedelics as mental health treatments
    Trump's embrace of psychedelics and cannabis is shaking up the GOP’s relationship with mind-altering substances.
    STAT · 3mo ago↗ source
  • STAT+: A biotech VC on what Eli Lilly saw in a struggling cancer startup for $3.2B
    What did Eli Lilly see in a struggling biotech startup that made the pharma giant want to pay billions for it? Bryan Roberts has some answers.
    STAT · 3mo ago↗ source
  • FDA unveils three psychedelic-focused commissioner vouchers
    The FDA said Friday it has issued new fast-track vouchers to three psychedelic companies, and its selections have come as a “surprise” to Wall Street. In an unusual move, the agency didn’t name the…
    Endpoints · 3mo ago↗ source
  • STAT+: Utah medical board calls for immediate suspension of state’s AI doctor experiment
    A Utah pilot to renew prescriptions using a bot faced backlash from the state's medical board, which called for an immediate suspension.
    STAT · 3mo ago↗ source
  • STAT+: Up and down the ladder: The latest comings and goings
    From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
    STAT · 3mo ago↗ source
  • Avalyn plots $182M IPO; WHO prequalifies Novartis' malaria drug
    Avalyn Pharma plots $182M IPO: The biotech, which is making inhaled versions of approved pulmonary fibrosis medicines, anticipates about $182 million in net proceeds if it prices its initial public…
    Endpoints · 3mo ago↗ source
  • Novartis pulls Pluvicto prostate cancer label expansion filing in the EU
    Novartis has withdrawn its EU application for Pluvicto's expansion into earlier prostate cancer treatment, despite US and UK approval for the same indication. The Swiss drugmaker failed to gain fav…
    Endpoints · 3mo ago↗ source
  • Exclusive: UC Berkeley startup bets on jumping genes for GLP-1 gene therapy
    The new generation of weight loss medicines does an unprecedented job of keeping off the pounds — if people stay on the drugs. Yet numerous studies suggest most of those who start taking GLP-1 drug…
    Endpoints · 3mo ago↗ source